Daxor Co. (NASDAQ:DXR) Short Interest Update

Daxor Co. (NASDAQ:DXR) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 9,000 shares, a growth of 7.1% from the December 15th total of 8,400 shares. Based on an average daily trading volume, of 16,800 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.5% of the company’s stock are short sold.

Institutional Investors Weigh In On Daxor

A hedge fund recently raised its stake in Daxor stock. Keyes Stange & Wooten Wealth Management LLC boosted its stake in Daxor Co. (NASDAQ:DXR) by 34.8% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 14,612 shares of the company’s stock after buying an additional 3,771 shares during the period. Keyes Stange & Wooten Wealth Management LLC owned approximately 0.30% of Daxor worth $126,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 1.34% of the company’s stock.

Daxor Trading Up 5.1 %

NASDAQ:DXR traded up $0.41 on Monday, hitting $8.50. 1,102 shares of the company’s stock were exchanged, compared to its average volume of 5,653. The firm has a 50-day moving average price of $8.56 and a 200-day moving average price of $8.80. Daxor has a 52 week low of $7.19 and a 52 week high of $10.02.

Daxor Company Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.